<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512834</url>
  </required_header>
  <id_info>
    <org_study_id>DAUHIRB-18-052</org_study_id>
    <nct_id>NCT03512834</nct_id>
  </id_info>
  <brief_title>Paclitaxel-Avelumab for Angiosarcoma</brief_title>
  <acronym>ASAP</acronym>
  <official_title>Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sung Yong Oh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dong-A University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of Avelumab when given in combination with paclitaxel as a first&#xD;
      line treatment for the patients with inoperable angiosarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Angiosarcomas are very rare tumors (incidence &lt; 1/100.000/year) of vascular or lymphatic&#xD;
      origin characterized by a clinical heterogeneity in terms of presentation and behavior.In&#xD;
      several prospective and retrospective studies, weekly paclitaxel showed promising activity in&#xD;
      patients with advanced or metastatic angiosarcoma. Given the important role of PD-L1 in the&#xD;
      suppression of T-cell responses, and the mode of action of avelumab which blocks the&#xD;
      interaction between PD-L1 and its receptors, avelumab is being developed as a potential&#xD;
      therapy for subjects with various tumors. In prior study cutaneous angiosarcoma patients with&#xD;
      a high infiltration of PD-1-positive cells with tumor site PD-L1 expression were more likely&#xD;
      to have favorable survival.&#xD;
&#xD;
      Therefore, antitumor activity of Avelumab as inhibitor of PD-1/PDL-1 interaction with&#xD;
      Paclitaxel, standard chemotherapy, might have more therapeutic improvement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Paclitaxel + Avelumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>CR+PR by RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 12 months</time_frame>
    <description>death event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>up to 12 months</time_frame>
    <description>By NCI-CTC v4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Angiosarcoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Paclitaxel+Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel combination with Avelumab for inoperable angiosarcoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity</description>
    <arm_group_label>Paclitaxel+Avelumab</arm_group_label>
    <other_name>BAVENCIO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.</description>
    <arm_group_label>Paclitaxel+Avelumab</arm_group_label>
    <other_name>TAXOL</other_name>
    <other_name>GENEXOL</other_name>
    <other_name>ANZATAX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent.&#xD;
&#xD;
          2. Male or female subjects aged ≥ 20 years.&#xD;
&#xD;
          3. Histologically or cytologically proven metastatic or locally advanced Angiosarcoma.&#xD;
&#xD;
          4. Inoperable Angiosarcoma&#xD;
&#xD;
          5. Chemo-naïve patient&#xD;
&#xD;
          6. ECOG performance status of 0 to 1 at trial entry and an estimated life expectancy of&#xD;
             at least 3 months.&#xD;
&#xD;
          7. Disease must be measurable with at least 1 measurable lesion by RECIST 1.1&#xD;
&#xD;
          8. Adequate hematological function defined by white blood cell (WBC) count ≥ 3 × 109/L&#xD;
             with absolute neutrophil count (ANC) ≥ 1.5 × 109/L, lymphocyte count ≥ 0.5 × 109/L,&#xD;
             platelet count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused).&#xD;
&#xD;
          9. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit&#xD;
             of normal range (ULN), an aspartate aminotransferase (AST), level ≤ 2.5 × ULN, and an&#xD;
             alanine aminotransferase (ALT) level ≤ 2.5 × ULN or, for subjects with documented&#xD;
             metastatic disease to the liver, AST and ALT levels&#xD;
&#xD;
             ≤ 5 × ULN.&#xD;
&#xD;
         10. Adequate renal function defined by an estimated creatinine clearance &gt; 30mL/min&#xD;
             according to the Cockcroft-Gault formula.&#xD;
&#xD;
         11. Highly effective contraception (that is, methods with a failure rate of less than 1%&#xD;
             per year) for both male and female subjects if the risk of conception exists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent treatment with a non-permitted drug (see Section 14)&#xD;
&#xD;
          2. Prior therapy with any antibody/drug targeting T cell co-regulatory proteins (immune&#xD;
             checkpoints) such as anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte antigen-4&#xD;
             (CTLA-4) antibody.&#xD;
&#xD;
          3. Concurrent anticancer treatment within 28 days before the start of trial treatment&#xD;
             (e.g., cytoreductive therapy, radiotherapy [with the exception of palliative bone&#xD;
             directed radiotherapy], immune therapy, or cytokine therapy except for erythropoietin)&#xD;
&#xD;
          4. Major surgery within 28 days before the start of trial treatment (excluding prior&#xD;
             diagnostic biopsy)&#xD;
&#xD;
          5. Use of hormonal agents within 7 days before the start of trial treatment.&#xD;
&#xD;
          6. Use of any investigational drug within 28 days before the start of trial treatment.&#xD;
&#xD;
          7. Subjects receiving immunosuppressive agents (such as steroids) for any reason should&#xD;
             be tapered off these drugs before initiation of the study treatment (with the&#xD;
             exception of patients with adrenal insufficiency, who may continue corticosteroids at&#xD;
             physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily). Steroids with&#xD;
             no or minimal systemic effect (topical, inhalation) are allowed.&#xD;
&#xD;
          8. Previous malignant disease other than the target malignancy to be investigated in this&#xD;
             trial within the last 5 years with the exception of basal or squamous cell carcinoma&#xD;
             of the skin or cervical carcinoma in situ.&#xD;
&#xD;
          9. Rapidly progressive disease (e.g., tumor lysis syndrome).&#xD;
&#xD;
         10. Active or history of central nervous system (CNS) metastases.&#xD;
&#xD;
         11. Receipt of any organ transplantation including allogeneic stem-cell transplantation.&#xD;
&#xD;
         12. Significant acute or chronic infections including, among others:&#xD;
&#xD;
               1. Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
                  acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
               2. Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV&#xD;
                  antibody tested positive).&#xD;
&#xD;
         13. Active or history of any autoimmune disease (subjects with diabetes Type I, vitiligo,&#xD;
             psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are&#xD;
             eligible) or immunodeficiencies.&#xD;
&#xD;
         14. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTCAE&#xD;
             v4.0), any history of anaphylaxis, or uncontrolled asthma (i.e., 3 or more features of&#xD;
             partly controlled asthma).&#xD;
&#xD;
         15. Persisting toxicity related to prior therapy Grade &gt; 1 NCI-CTCAE v4.0, however sensory&#xD;
             neuropathy&#xD;
&#xD;
             ≤ Grade 2 is acceptable.&#xD;
&#xD;
         16. Pregnancy or breast feeding.&#xD;
&#xD;
         17. Known alcohol or drug abuse.&#xD;
&#xD;
         18. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (New York Heart&#xD;
             Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia&#xD;
             requiring medication.&#xD;
&#xD;
         19. All other significant diseases (e.g., inflammatory bowel disease), which, in the&#xD;
             opinion of the investigator, might impair the subject's tolerance of trial treatment.&#xD;
&#xD;
         20. Any psychiatric condition that would prohibit the understanding or rendering of&#xD;
             informed consent.&#xD;
&#xD;
         21. Legal incapacity or limited legal capacity.&#xD;
&#xD;
         22. Vaccination within 4 weeks of the first dose of avelumab and while on study is&#xD;
             prohibited except for administration of inactivated vaccines (e.g. inactivated&#xD;
             influenza vaccines).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SUNG YONG OH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SUNG YONG OH, MD</last_name>
    <phone>+82-51-240-2808</phone>
    <email>drosy@dau.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sung Yong Oh</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SUNG YONG OH, Professor</last_name>
      <email>drosy@dau.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>April 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2018</study_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University Hospital</investigator_affiliation>
    <investigator_full_name>Sung Yong Oh</investigator_full_name>
    <investigator_title>Dong-A University Hospital</investigator_title>
  </responsible_party>
  <keyword>angiosarcoma</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>avelumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

